<DOC>
	<DOCNO>NCT01281722</DOCNO>
	<brief_summary>Melanoma aggressive skin cancer , propensity metastasize , resistant current therapeutic regimen . Incidence rate melanoma patient MDM ( Mal De Maleda , SLURP-1 mutation ) much high normal counterpart . SLURP-1 ( lymphocyte antigen 6/urokinase-type plasminogen activator receptor related protein-1 ) allosteric agonist nicotinic acetylcholine receptor ( nAchR ) regulate epidermal homeostasis T-cell function . The preliminary result compare human peripheral blood mononuclear cell ( PBMCs ) 4 affect 15 unaffected member family MDM reveal T-cell activation impair PBMCs heterozygous homozygous SLURP-1 G86R mutation . ( 2 affect member develop melanoma . ) Since currently effective treatment metastatic melanoma , identify novel molecular mechanism may lead development new treatment metastatic melanoma . Previous study show melanoma stem cell ( MSCs ) crucial melanoma pathogenesis : 1.Melanoma contains ABCB5 , CD133 ABCG2 positive cell enhance tumorigenic potential . 2.Higher frequency cell capable initiate melanoma xenograft use IL2Rγ-/- NOD SCID mouse . These data confirm interaction T cell MSCs . In project , investigate role SLURP-1 melanoma MSCs . Investigating verify interaction T-cells patient MDM melanoma cell confirm SLURP-1 function tumorigenesis xenotransplant mouse ( IL2Rγ-/- NOD SCID ) model . To reveal role SLURP-1 silence melanoma cell line use A2058 , A375 MeWo mwlanima cell line also ABCB5+ melanoma cell ABCB5- melanoma cell tumorigenesis , apoptosis , angiogenesis , proliferation , melanosphere formation assay . The aim project investigate role molecular mechanism SLURP-1 melanoma carcinogenesis , may improve development novel treatment melanoma .</brief_summary>
	<brief_title>Role SLURP-1 Melanoma Melanoma Stem Cells</brief_title>
	<detailed_description>Cutaneous melanoma aggressive neoplasm refractory traditional therapy , especially metastatic stage . Furthermore , incidence continuously increase last decade ( 1 ) . Melanomas develop multistep process normal melanocyte proceeds nevi radial vertical growth phase tumor ( 2 ) . During process , melanoma characterize certain well-defined genetic alteration well frequent chromosomal aberration associate tumor progression ( 3 ) . However , molecular mechanism involve carcinogenesis progression melanoma complex entirely clear ( 4 ) . Because intractability metastatic melanomas 14 % patient survive 5 year effective treatment ( 2 ) , understand underlie molecular mechanism involve melanoma identify molecular marker may lead improvement therapeutic approach metastatic melanoma . Mal de Meleda ( MDM ; OMIM 248300 ) rare autosomal recessive disorder characterize erythema hyperkeratosis palm sol , extend dorsal aspect hand foot ( know transgrediens ) , perioral erythema psoriasiform plaque elbow knee . ( 5-7 ) Homozygous mutation SLURP1 gene ( previously know ARS component B ) encode lymphocyte antigen 6/urokinase-type plasminogen activator receptor relate protein-1 ( SLURP-1 ) identify cause MDM . ( 8-10 ) Mutations SLURP1 gene affect expression , integrity stability SLURP-1 upper layer epidermis culture mature keratinocytes . ( 11 ) Other study also demonstrate SLURP-1 act positive allosteric ligand 7-nAchR keratinocytes , elicit proapoptotic activity differentiation . ( 12,13 ) As well epidermis keratinocytes , expression SLURP-1 find T cell , B cell , dendritic cell macrophage . ( 14-15 ) Malignant melanoma ( MM ) report predominant cutaneous malignancy occur hyperkeratotic area patient MDM . ( 16 ) The incidence MM MDM significantly high general population . ( 17 ) At least six case MM report patient MDM ; 27-29 two report case sibling . ( 18 ) The possible explanation high incidence MM patient MDM include : ( ) lack proapoptotic effect SLURP-1 ; ( ii ) defective T-cell activation tumour monitoring ; ( iii ) prolong inflammation hyperkeratotic skin . The previous study show peripheral blood mononuclear cell ( PBMCs ) heterozygous homozygous SLURP-1 G86R mutation defective T-cell activation . This restored addition 0•5 μg mL−1 recombinant human SLURP-1 protein . ( 19 ) Previous study show putative monoclonal antibody recognize ABCB5 use isolate melanoma stem cell ( MSCs ) . ( 20 ) In study , investigator investigate role SLURP-1 melanoma cell ( include MSC ) also interaction melanoma cell T-cells . Aims： 1 . To evaluate significance correlation SLURP-1 expression melanoma cell melanoma metastasis human tissue mouse metastasis model . 2 . To assess function SLURP-1 protein melanoma cell melanoma stem cell . 3 . To investigate interaction T-cells SLURP-1 mutation melanoma cell / MSCs . 4 . Confirm biological effect SLURP-1 melanoma cell / MSCs . 5 . To investigate relationship SLURP-1 overexpression melanoma cancer biology . References 1 . Gray-Schopfer V , Wellbrock C , Marais R. Melanoma biology new target therapy . Nature 2007 ; 445 : 851-7 . 2 . Miller AJ , Mihm MC . Melanoma . N Engl J Med 2006 ; 355 : 51-65 . 3 . Jonsson G , et al . Genomic profile malignant melanoma use tiling-resolution array CGH . Oncogene 2007 ; 6 : 4738-48 . 4 . Bemis LT , Chen R , Amato CM et al . MicroRNA-137 target microphthalmia-associated transcription factor melanoma cell line . Cancer Res 2008 ; 68 : 1362-8 . 5 . Lucker GP , Van De Kerkhof PC , Steijlen PM . The hereditary palmoplantar keratoses : update review classification . Br J Dermatol 1994 ; 131:1-14 . 6 . Bergman R , Bitterman-Deutsch O , Fartasch M et al . Mal de Meleda keratoderma pseudoainhum . Br J Dermatol 1993 ; 128:207-12 . 7 . Jee SH , Lee YY , Wu YC et al . Report family mal de Meleda Taiwan : clinical , histopathological immunological study . Dermatologica 1985 ; 171:30-7 . 8 . Fischer J , Bouadjar B , Heilig R et al . Mutations gene encode SLURP-1 Mal de Meleda . Hum Mol Genet 2001 ; 10:875-80 . 9 . Ward KM , Yerebakan O , Yilmaz E et al . Identification recurrent mutation ARS ( component B ) gene encode SLURP-1 two family mal de Meleda . J Invest Dermatol 2003 ; 120:96-8 . 10 . Mastrangeli R , Donini S , Kelton CA et al . ARS component B : structural characterization , tissue expression regulation gene protein ( SLURP-1 ) associate mal de Meleda . Eur J Dermatol 2003 ; 13:560-70 . 11 . Favre B , Plantard L , Aeschbach L et al . SLURP1 late marker epidermal differentiation absent mal de Meleda . J Invest Dermatol 2007 ; 127:301-8 . 12 . Grando SA . Basic clinical aspect non-neuronal acetylcholine : biological clinical significance non-canonical ligands epithelial nicotinic acetylcholine receptor . J Pharmacol Sci 2008 ; 106:174-9 . 13 . Arredondo J , Chernyavsky AI , Webber RJ et al . Biological effect SLURP-1 human keratinocytes . J Invest Dermatol 2005 ; 125:1236-41 . 14 . Moriwaki Y , Yoshikawa K , Fukuda H et al . Immune system expression SLURP-1 SLURP-2 , two endogenous nicotinic acetylcholine receptor ligands . Life Sci 2007 ; 80:2365-8 . 15 . Kawashima K , Yoshikawa K , Fujii YX et al . Expression function gene encode cholinergic component murine immune cell . Life Sci 2007 ; 80:2314-19 . 16 . Nakajima K , Nakano H , Takiyoshi N et al . Papillon-Lefèvre syndrome malignant melanoma . A high incidence melanoma development Japanese palmoplantar keratoderma patient . Dermatology 2008 ; 217:58-62 . 17 . Sartore L , Bordignon M , Bassetto F et al . Melanoma skin affect keratoderma palmoplantaris hereditaria ( mal de Meleda ) : treatment excision graft . J Am Acad Dermatol 2009 ; 61:161-3 . 18 . Mozzillo N , Nunziata CA , Caraco C et al . Malignant melanoma develop area hereditary palmoplantar keratoderma ( mal de Meleda ) . J Surg Oncol 2003 ; 84:229-33 . 19 . Tjiu JW , Lin PJ , Wu WH et al . SLURP1 mutation-impaired T-cell activation family mal de Meleda . Br J Dermatol . 2010 Sep 21 20 . Schatton T , Murphy GF , Frank NY et al . Identification cell initiate human melanoma . Nature . 2008 Jan 17 ; 451 ( 7176 ) :345-9</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Clinical diagnosis melanoma Disease NTU hospital ( group case ) healthy adult ( group control ) two group whose age young 20 old tha 95 year old Clinical diagnosis nonmelanoma Disease NTU hospital ( group case )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>healthy adult</keyword>
	<keyword>melanoma</keyword>
</DOC>